1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. SGLT
  4. SGLT2 Isoform



SGLT2 Related Products (21):

Cat. No. Product Name Effect Purity
  • HY-10450
    Inhibitor 99.87%
    Dapagliflozin (BMS-512148), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine.
  • HY-N0142
    Inhibitor 99.67%
    Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.
  • HY-N0143
    Inhibitor 99.82%
    Phlorizin is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively.
  • HY-15461
    Inhibitor 99.85%
    Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2.
  • HY-14894
    Inhibitor 99.78%
    Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively.
  • HY-10449
    Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM).
  • HY-12611
    Sergliflozin etabonate
    Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor.
  • HY-109018B
    Velagliflozin proline hydrate
    Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018).
  • HY-10450A
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)
    Inhibitor 99.99%
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate.
  • HY-N4100
    Inhibitor 98.85%
    Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd, Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope.
  • HY-14945
    Remogliflozin etabonate
    Inhibitor 99.64%
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively.
  • HY-15461A
    Ertugliflozin L-pyroglutamic acid
    Inhibitor 99.77%
    Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2.
  • HY-109018
    Inhibitor 99.92%
    Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
  • HY-10450S
    Inhibitor 98.08%
    Dapagliflozin D5 (BMS-512148 D5) is a deuterium labeled Dapagliflozin.
  • HY-138944
    SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .
  • HY-109144
    Inhibitor 98.01%
    Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
  • HY-10449A
    Luseogliflozin hydrate
    Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM.
  • HY-117010
    Kushenol K
    Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens.
  • HY-106158
    T-1095 is a selective and orally active Na+-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively.
  • HY-12608
    TA-1887 (JNJ-39933673) is a highly potent, selective and orally active SGLT2 inhibitor (IC50: 1.4 nM) with antihyperglycemic effects.